Johnston KM - Search Results

1

Cost-effectiveness of rituximab in follicular lymphoma.

Johnston KM, Bolbocean C, Connors J, Peacock S. Johnston KM, et al. Expert Rev Pharmacoecon Outcomes Res. 2012 Oct;12(5):569-77. doi: 10.1586/erp.12.57. Epub 2012 Nov 11. Expert Rev Pharmacoecon Outcomes Res. 2012. PMID: 23140274 Review.

2

Why should dentists screen for oral cancer?

Musa Z, Johnston K, Peacock S, Rosin MP, Elwood JM. Musa Z, et al. J Can Dent Assoc. 2008 Apr;74(3):243-4. J Can Dent Assoc. 2008. PMID: 18387265 Free article. No abstract available.

3

Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study).

Mabasa VH, Taylor SC, Chu CC, Moravan V, Johnston K, Peacock S, Knowling M. Mabasa VH, et al. J Oncol Pharm Pract. 2008 Sep;14(3):105-12. doi: 10.1177/1078155208088695. Epub 2008 Jun 4. J Oncol Pharm Pract. 2008. PMID: 18524863

4

Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.

Johnston KM, Marra CA, Connors JM, Najafzadeh M, Sehn L, Peacock SJ. Johnston KM, et al. Value Health. 2010 Sep-Oct;13(6):703-11. doi: 10.1111/j.1524-4733.2010.00737.x. Epub 2010 Jun 7. Value Health. 2010. PMID: 20561333 Free article.

5

Expanding access to HAART: a cost-effective approach for treating and preventing HIV.

Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, Briggs A, Montaner JS. Johnston KM, et al. AIDS. 2010 Jul 31;24(12):1929-35. doi: 10.1097/QAD.0b013e32833af85d. AIDS. 2010. PMID: 20588171

6

Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE).

Najafzadeh M, Johnston KM, Peacock SJ, Connors JM, Marra MA, Lynd LD, Marra CA. Najafzadeh M, et al. Among authors: johnston km. BMC Health Serv Res. 2013 Oct 31;13:454. doi: 10.1186/1472-6963-13-454. BMC Health Serv Res. 2013. PMID: 24176050 Free PMC article.

7

Cost-effectiveness of therapies for melanoma.

Johnston KM, McPherson E, Osenenko K, Vergidis J, Levy AR, Peacock S. Johnston KM, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr;15(2):229-42. doi: 10.1586/14737167.2015.1017563. Epub 2015 Feb 23. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25703441 Review.

8

Treatment patterns and costs of care for patients with relapsed and refractory Hodgkin lymphoma treated with brentuximab vedotin in the United States: A retrospective cohort study.

Szabo SM, Hirji I, Johnston KM, Juarez-Garcia A, Connors JM. Szabo SM, et al. Among authors: johnston km. PLoS One. 2017 Oct 9;12(10):e0180261. doi: 10.1371/journal.pone.0180261. eCollection 2017. PLoS One. 2017. PMID: 28991893 Free PMC article.

9

Projecting long-term graft and patient survival after transplantation.

Levy AR, Briggs AH, Johnston K, MacLean JR, Yuan Y, L'Italien GJ, Kalsekar A, Schnitzler MA. Levy AR, et al. Value Health. 2014 Mar;17(2):254-60. doi: 10.1016/j.jval.2014.01.001. Value Health. 2014. PMID: 24636384 Free article.

10

Budget Impact Analysis of Prolonged Half-Life Recombinant FVIII Therapy for Hemophilia in the United States.

McMullen S, Buckley B, Hall E 2nd, Kendter J, Johnston K. McMullen S, et al. Value Health. 2017 Jan;20(1):93-99. doi: 10.1016/j.jval.2016.09.2396. Epub 2016 Nov 17. Value Health. 2017. PMID: 28212975 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

148 results

Search Page